Both studies met all primary immunogenicity endpoints, demonstrating robust immune responses against certain invasive meningococcal B strains after the vaccine dose series. Safety and tolerability data from both
Researchers found that being overweight more than doubled the risk of bowel cancer in people with Lynch Syndrome, an inherited genetic disorder which affects genes responsible for detecting
The transaction will continue to bolster Hi-Tech’s leading Sports Nutrition and Weight Loss arsenal and expand its position as the leader in Diet & Energy products and continues
IXEMPRA is indicated as monotherapy or in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory
Under this Agreement, the Company will manufacture and supply Alferon N Injection to physicians and patients through Armada’s national network of specialty pharmacies. Armada has agreed to provide
With the increase, NRC-IRAP’s total non-refundable financial contributions to DelMar total CDN$420,000 to date. "We are very pleased with the continued support to accelerate and expand our non-clinical
The complaint, filed by the U.S. Department of Justice, sought a permanent injunction against the company and its owners for unlawfully manufacturing and distributing unapproved new drugs, misbranded
Strensiq is the first approved treatment for HPP, an ultra-rare, genetic, metabolic disease in which patients experience devastating, progressive effects on multiple organs of the body, leading to
It was recently approved by the U.S. Food and Drug Administration (FDA) for the once-daily, topical treatment of acne vulgaris. Epiduo Forte Gel offers patients and physicians a
Participants in the Phase 3, open-label extension study, B-YOND, maintained low bleeding rates with one to two week prophylaxis regimens, according to data from an interim analysis. Investigators
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.